Novel immunotherapies for hematologic malignancies

Abstract

Summary The immune system is designed to discriminate between self and tumor tissue. Through genetic recombination, there is fundamentally no limit to the number of tumor antigens that immune cells can recognize. Yet, tumors use a variety of immunosuppressive mechanisms to evade immunity. Insight into how the immune system interacts with tumors is expanding rapidly and has accelerated the translation of immunotherapies into medical breakthroughs. Herein, we appraise the state of the art in immunotherapy with a focus on strategies that exploit the patient’s immune system to kill cancer. We review various forms of immune-based therapies, which have shown significant promise in patients with hematological malignancies, including (i) conventional monoclonal therapies like rituximab, (ii) engineered monoclonal antibodies called bispecific T cell engagers (BiTEs), (iii) monoclonal antibodies and pharmaceutical drugs that block inhibitory T-cell pathways (i.e. PD-1, CTLA-4 and IDO), and (iv) adoptive cell transfer (ACT) therapy with T cells engineered to express chimeric antigen receptors (CARs) or T-cell receptors (TCRs). We also assess the idea of using these therapies in combination and conclude by suggesting multi-prong approaches to improve treatment outcomes and curative responses in patients.

Hepatocellular carcinoma following direct anti-viral for hepatitis C treatment: a report of an Egyptian case series

“…[13] A recent in vivo study reported the IFN's ability to synergize the apoptotic, autophagic as well as the anti-proliferative action of cisplatin. [14] Autophagy has been shown to be induced in HCC cell lines when treated with IFNα2b in a dose-dependent manner. [15] Of note, autophagic cell death had been suggested as one of the anti-cancer actions of anti-cancer therapeutics.…”

Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target

“…Ovarian cancer is, however, an immunogenic tumor (2-10). Therefore, immunotherapies offer great promise to reverse this dismal prognosis (11, 12). …”

Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic

“…For example, patients with melanoma experienced robust antitumor responses after treatment with a combination of antibodies that block co-inhibitory molecules PD-1 and CTLA-4 on exhausted T cells [1]. Advances in gene therapy also show that the patient's T cells can be engineered with a tumor antigen-specific receptor [2–4]. Adoptive transfer of these engineered T cells into patients with acute lymphocytic leukemia mediated treatment outcomes of record efficacy, resulting in complete remission in ~90 % of children and adult patients [5, 6].…”